Christine Flefleh
About
In The Last Decade
Christine Flefleh
13 papers receiving 399 citations
Peers
Comparison fields: 5 of 55
- Oncology 159
- Hematology 139
- Molecular Biology 111
- Genetics 104
- Rheumatology 80
Countries citing papers authored by Christine Flefleh
This map shows the geographic impact of Christine Flefleh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Flefleh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Flefleh more than expected).
Fields of papers citing papers by Christine Flefleh
This network shows the impact of papers produced by Christine Flefleh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Flefleh. The network helps show where Christine Flefleh may publish in the future.
Co-authorship network of co-authors of Christine Flefleh
This figure shows the co-authorship network connecting the top 25 collaborators of Christine Flefleh. A scholar is included among the top collaborators of Christine Flefleh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Flefleh. Christine Flefleh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development | 8 |
| 2 | 28 | |
| 3 | 113 | |
| 4 | 60 | |
| 5 | BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo | 38 |
| 6 | 66 | |
| 7 | 22 | |
| 8 | 14 | |
| 9 | 5 | |
| 10 | Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668 | 3 |
| 11 | 1 | |
| 12 | 9 | |
| 13 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. | 42 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.